BEVATAS 400MG

Product Description

1. What is Bevatas 400 mg used for?
It is an anti-cancer medicine used as part of treatment for several cancers, including colorectal, lung, kidney, ovarian and cervical cancers, depending on the doctor's prescribed treatment protocol.

2. What is the composition of Bevatas 400 mg?
Each vial contains Bevacizumab 400 mg. The 400 mg presentation contains 16 mL solution.

3. How does Bevatas work?
Bevacizumab blocks VEGF-mediated blood-vessel formation, thereby reducing the formation of new blood vessels that tumors can use for growth.

4. How is Bevatas 400 mg administered?
It is administered as an intravenous infusion by a qualified healthcare professional. It should not be given as an IV push or bolus.

5. Can Bevatas be given with chemotherapy?
Yes. Bevacizumab is commonly used in combination with other anti-cancer medicines, depending on the cancer type and treatment protocol.

6. What are the common side effects?
Possible adverse effects include high blood pressure, nosebleeds, protein in urine, weakness, reduced appetite and blood-clot-related complications. More serious complications can also occur, so medical monitoring is important.

7. Does Bevatas affect blood pressure?
Yes. Bevacizumab can cause or worsen high blood pressure, and blood pressure should be monitored during treatment.

8. How should Bevatas 400 mg be stored?
Store refrigerated at 2C8C. Do not freeze or shake the vial and keep it protected from light in its outer carton.

9. Can Bevatas 400 mg be self-administered?
No. It is an IV infusion and should be prepared and administered by trained healthcare professionals.

10. Is Bevatas 400 mg a prescription medicine?
Yes. It should be used only under the supervision of an oncologist or other qualified healthcare professional.

11. Can Bevatas affect wound healing?
Yes. Bevacizumab can interfere with wound healing, so the treating physician needs to consider recent or planned surgery before administering it.

12. Is Bevatas 400 mg a chemotherapy drug?
It is not a conventional cytotoxic chemotherapy drug. It is a targeted biological therapya monoclonal antibody that inhibits VEGFand is often used alongside chemotherapy.

Catalog-ready short description

BEVATAS 400 MG | Bevacizumab 400 mg | 16 mL Vial | Anti-VEGF Monoclonal Antibody | Intas Pharmaceuticals Ltd. | Cold Chain 28C | Prescription Medicine.